Compare Vanguard Value Index Fund ETF (VTV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Value Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Vanguard Value Index Fund ETF is far larger — about 129.9× GeneDx Holdings Corp's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Value Index Fund ETF for 142 Days and GeneDx Holdings Corp for 19 Days on average.
| VTV | WGS | |
|---|---|---|
Market Cap | $262.40B | $2.02B |
Volume | 3,293,281 | 734,640 |
52-Week High | $227.51 | $167.51 |
52-Week Low | $182.86 | $34.51 |
Typical Hold Time | 142 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Value ETF (VTV) trades at $219.63, up 0.65% today, with a bearish technical signal but bullish moving averages. The fund offers a 2.3% dividend yield and has attracted institutional buying, including recent positions from QRG Capital Management and Blue Edge Capital. Value stocks have outperformed growth in 2026, with VTV leading among large-cap value ETFs due to its low 0.03% expense ratio and diversification away from tech mega-caps.
VTV presents a defensive opportunity amid market rotation from growth to value, supported by income appeal and lower volatility. Risks include prolonged underperformance versus the S&P 500 over the past decade and sensitivity to interest rate changes. The fund's reliance on traditional value sectors may lag if growth stocks rebound.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
